Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: A randomised, double-blind crossover trial

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 10, 2010, Pages 1135-1140

  Weber, Markus ^a,b   Goldman, B ^a   Truniger, S ^b  

^a ALS Clinic   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; PLACEBO; TETRAHYDROCANNABINOL;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; APPETITE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MUSCLE CRAMP; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP; TREATMENT OUTCOME; VISUAL ANALOG SCALE; CROSSOVER PROCEDURE; DRUG EFFECT; HOSPITALIZATION; MIDDLE AGED; SLEEP DISORDER;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; APPETITE; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE CRAMP; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; TETRAHYDROCANNABINOL;

EID: 77958147396     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.200642     Document Type: Article

References (38)

1. Heiman-Patterson TD, Rampal N, Brannagan, et al. The spectrum of patient symptoms in ALS and symptom management. Neurology 2000;56(8 Suppl 3):A199.
2. Forshew DA, Bromberg MB. A survey of clinicians' practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:258-63.
3. Bedlack RS, Pastula DM, Hawes J, et al. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 2009;10:210-5.
4. Food and Drug Administration. FDA orders unapproved quinine drugs from the market and cautions consumers about 'off-label' use of quinine to treat leg cramps. 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ ucm108799.htm (accessed 10 Oct 2009).
5. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364-70.
6. Desnuelle C, Dib M, Garrel C, et al. Double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001;2:9-18. (Pubitemid 32472143)
7. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-31. (Pubitemid 26161204)
8. Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47:1383-8.
9. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-8.
10. Amtmann D, Weydt P, Johnson KL, et al. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21:95-104. (Pubitemid 38560946)
11. Gelinas DF, Miller RG, Abood M. Pilot study of safety and tolerability of delta 9-THC (Marinol) treatment for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3(Suppl 2):23-4.
12. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17:179-202. (Pubitemid 36286534)
13. Obi T, Mizoguchi K, Matsuoka H, et al. Muscle cramp as the result of impaired GABA function - an electrophysiological and pharmacological observation. Muscle Nerve 1993;16:1228-31. (Pubitemid 23304861)
14. Baldissera F, Cavallari P, Dworzak F. Motor neuron 'bistability.' A pathogenetic mechanism for cramps and myokymia. Brain 1994;117:929-39.
15. Khan SI, Burne JA. Reflex inhibition of normal cramp following electrical stimulation of the muscle tendon. J Neurophysiol 2007;98:1102-7.
16. Parisi L, Serrao M, Rossi P, et al. Afterdischarge activity in neuropathic patients with frequent muscle cramps. Acta Neurol Scand 2000;102:359-62.
17. Vucic S, Kiernan MC. Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 2006;117:1458-66. (Pubitemid 43947716)
18. Newman Z, Malik P, Wu TY, et al. Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci 2007;25:1619-30. (Pubitemid 46549999)
19. Zhao P, Ignacio S, Beattie EC, et al. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosc 2008;27:572-9. (Pubitemid 351246277)
20. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9.
21. Weber M, Feinberg D. Treatment of cramps in amyotrophic lateral sclerosis/motor neuron disease. (Protocol). Cochrane Database Sys Rev 2003.
22. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21. (Pubitemid 29502501)
23. Jenkinson C, Fitzpatrick R, Brennan C, et al. Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ-40. Amyotroph Lateral Scler Other Motor Neuron Disord 1999;1:33-40.
24. Douglass AB, Bornstein R, Nino-Murcia G, et al. The sleep disorders questionnaire. I: Creation and multivariate structure of SDQ. Sleep 1994;17:160-7.
25. Chang VT, Xia Q, Kasimis B. The functional assessment of anorexia/cachexia therapy (FAACT) appetite scale in veteran cancer patients. J Support Oncol 2005;3:377-82. (Pubitemid 41448264)
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
27. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9. (Pubitemid 41362120)
28. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245-50. (Pubitemid 39350025)
29. Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62:1105-9. (Pubitemid 38456503)
30. Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy- delta9-tetrahydrocannabinol in humans. Ther Drug Monit 1998;20:570-6.
31. Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxydelta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 1999;23:323-32. (Pubitemid 29418298)
32. Bilsland LG, Dick JR, Pryce G, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J 2006;20:1003-5. (Pubitemid 44943930)
33. van der Stelt M, Veldhuis WB, Bar PR, et al. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001;21:6475-9.
34. Raman C, McAllister SD, Rizvi G, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:33-9. (Pubitemid 38618733)
35. Shoemaker JL, Seely KA, Reed RL, et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007;101:87-98.
36. Weydt P, Hong S, Witting A, et al. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:182-4. (Pubitemid 41419206)
37. Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006;6:12.
38. Rossi S, De Chiara V, Musella A, et al. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;19:1-8.